Chronic graft-versus-host disease (GVHD) can be associated with significant morbidity, in
part because of nonreversible fibrosis, which impacts physical functioning (eye, skin, lung
manifestations) and mortality (lung, gastrointestinal manifestations). Progress in preventing
severe morbidity and mortality associated with chronic GVHD is limited by a complex and
incompletely understood disease biology and a lack of prognostic biomarkers. Likewise,
treatment advances for highly morbid manifestations remain hindered by the absence of …